Timothy J. Perry, O.d., P.c. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 120 Benjamin H Hill Dr W, Fitzgerald, GA 31750 Phone: 229-423-0159 Fax: 229-423-0165 |
Colony Optical Optometrist Medicare: Not Enrolled in Medicare Practice Location: 708 S Grant St, Suite #18, Fitzgerald, GA 31750 Phone: 229-423-5556 Fax: 229-423-5179 |
Eyesight Associates Optometrist Medicare: Not Enrolled in Medicare Practice Location: 182 Perry House Rd, Suite G, Fitzgerald, GA 31750 Phone: 229-423-0481 Fax: 229-423-7463 |
Dr. Timothy Jay Perry, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 120 Benjamin H Hill Dr W, Fitzgerald, GA 31750 Phone: 229-563-7870 Fax: 229-244-5287 |
News Archive
Giving severely malnourished children antibiotics in addition to nutritional therapy significantly improves their chances of making a full recovery compared with nutritional therapy alone, say researchers.
At the Organization of Human Brain Mapping's 16th Annual Meeting (Barcelona, Spain, June 6-10), Elekta unveiled its next generation magnetoencephalography system, Elekta Neuromag TRIUX. A platform that addresses key requirements critical for monitoring normal and abnormal brain activity, Elekta Neuromag TRIUX was designed to operate in virtually any clinical environment – an advance welcomed by the growing number of Elekta Neuromag clinical and research facilities worldwide.
Noting that the Global Health Initiative (GHI) leadership and the three core entities of GHI - USAID, the Centers for Disease Control and Prevention (CDC) and PEPFAR - announced the closure of the GHI office and an end to the initiative's current phase on July 3, Serra Sippel, president of the Center for Health and Gender Equity, writes in the Huffington Post's "Politics" blog that "the three agencies will be responsible for ensuring that the GHI principles are implemented in the field to achieve global health goals."
New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.
A brain circuit that underlies feelings of stress and anxiety shows promise as a new therapeutic target for alcoholism, according to new studies by researchers at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health (NIH).
› Verified 6 days ago